Literature DB >> 32359794

Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence.

Annetine C Gelijns1, Alan J Moskowitz2, Patrick T O'Gara3, Gennaro Giustino2, Michael J Mack4, Donna M Mancini2, Emilia Bagiella2, Judy Hung5, Gorav Ailawadi6, Martin B Leon7, Michael A Acker8, John H Alexander9, Neal W Dickert10, Wendy C Taddei-Peters11, Marissa A Miller11.   

Abstract

OBJECTIVES: Two trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation.
METHODS: The National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives.
RESULTS: Transcatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team.
CONCLUSIONS: Given the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  functional mitral regurgitation; mitral valve; randomized trial; transcatheter mitral valve repair

Year:  2020        PMID: 32359794      PMCID: PMC7935447          DOI: 10.1016/j.jtcvs.2020.02.132

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  16 in total

Review 1.  Defining "severe" secondary mitral regurgitation: emphasizing an integrated approach.

Authors:  Paul A Grayburn; Blasé Carabello; Judy Hung; Linda D Gillam; David Liang; Michael J Mack; Patrick M McCarthy; D Craig Miller; Alfredo Trento; Robert J Siegel
Journal:  J Am Coll Cardiol       Date:  2014-12-30       Impact factor: 24.094

Review 2.  Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance.

Authors:  William A Zoghbi; David Adams; Robert O Bonow; Maurice Enriquez-Sarano; Elyse Foster; Paul A Grayburn; Rebecca T Hahn; Yuchi Han; Judy Hung; Roberto M Lang; Stephen H Little; Dipan J Shah; Stanton Shernan; Paaladinesh Thavendiranathan; James D Thomas; Neil J Weissman
Journal:  J Am Soc Echocardiogr       Date:  2017-03-14       Impact factor: 5.251

3.  Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial.

Authors:  Suzanne V Arnold; Khaja M Chinnakondepalli; John A Spertus; Elizabeth A Magnuson; Suzanne J Baron; Saibal Kar; D Scott Lim; Jacob M Mishell; William T Abraham; JoAnn A Lindenfeld; Michael J Mack; Gregg W Stone; David J Cohen
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

4.  Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.

Authors:  Michael J Mack; William T Abraham; JoAnn Lindenfeld; Steven F Bolling; Ted E Feldman; Paul A Grayburn; Samir R Kapadia; Patrick M McCarthy; D Scott Lim; James E Udelson; Michael R Zile; James S Gammie; A Marc Gillinov; Donald D Glower; David A Heimansohn; Rakesh M Suri; Jeffrey T Ellis; Yu Shu; Saibal Kar; Neil J Weissman; Gregg W Stone
Journal:  Am Heart J       Date:  2018-08-01       Impact factor: 4.749

5.  Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years.

Authors:  Bernard Iung; Xavier Armoiry; Alec Vahanian; Florent Boutitie; Nathan Mewton; Jean-Noël Trochu; Thierry Lefèvre; David Messika-Zeitoun; Patrice Guerin; Bertrand Cormier; Eric Brochet; Hélène Thibault; Dominique Himbert; Sophie Thivolet; Guillaume Leurent; Guillaume Bonnet; Erwan Donal; Nicolas Piriou; Christophe Piot; Gilbert Habib; Frédéric Rouleau; Didier Carrié; Mohammed Nejjari; Patrick Ohlmann; Christophe Saint Etienne; Lionel Leroux; Martine Gilard; Géraldine Samson; Gilles Rioufol; Delphine Maucort-Boulch; Jean François Obadia
Journal:  Eur J Heart Fail       Date:  2019-11-18       Impact factor: 15.534

6.  Surgical treatment of moderate ischemic mitral regurgitation.

Authors:  Peter K Smith; John D Puskas; Deborah D Ascheim; Pierre Voisine; Annetine C Gelijns; Alan J Moskowitz; Judy W Hung; Michael K Parides; Gorav Ailawadi; Louis P Perrault; Michael A Acker; Michael Argenziano; Vinod Thourani; James S Gammie; Marissa A Miller; Pierre Pagé; Jessica R Overbey; Emilia Bagiella; François Dagenais; Eugene H Blackstone; Irving L Kron; Daniel J Goldstein; Eric A Rose; Ellen G Moquete; Neal Jeffries; Timothy J Gardner; Patrick T O'Gara; John H Alexander; Robert E Michler
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

7.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

Review 8.  Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials.

Authors:  Paul A Grayburn; Anna Sannino; Milton Packer
Journal:  JACC Cardiovasc Imaging       Date:  2018-12-12

9.  Institutional Experience With Transcatheter Mitral Valve Repair and Clinical Outcomes: Insights From the TVT Registry.

Authors:  Adnan K Chhatriwalla; Sreekanth Vemulapalli; David R Holmes; Dadi Dai; Zhuokai Li; Gorav Ailawadi; Donald Glower; Saibal Kar; Michael J Mack; Jennifer Rymer; Andrzej S Kosinski; Paul Sorajja
Journal:  JACC Cardiovasc Interv       Date:  2019-07-22       Impact factor: 11.195

10.  Transcatheter Mitral-Valve Repair in Patients with Heart Failure.

Authors:  Gregg W Stone; JoAnn Lindenfeld; William T Abraham; Saibal Kar; D Scott Lim; Jacob M Mishell; Brian Whisenant; Paul A Grayburn; Michael Rinaldi; Samir R Kapadia; Vivek Rajagopal; Ian J Sarembock; Andreas Brieke; Steven O Marx; David J Cohen; Neil J Weissman; Michael J Mack
Journal:  N Engl J Med       Date:  2018-09-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.